Matsuda Masaru sold $92K of ARQT

Matsuda Masaru (See Remarks) sold 3,674 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.00 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Matsuda Masaru
Published Sep 18, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to move ARQT shares.

02

Market read

Small insider sell with minimal market relevance.

03

What to watch

Potential tax planning via 10b5‑1; not indicative of confidence.

Relevance 2/10Novelty 4/10Timing: post‑market 2026‑09‑16

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Officer Matsuda Masaru sold 3,674 shares of Arcutis Biotherapeutics for $91,853 via a 10b5‑1 plan.

Expected impact

No material price move expected.

Evidence & confidence

The sale is under $100K and represents a small fraction of holdings; such routine disposals rarely affect stock price.

Market effects

No broader sector impact; biotech sector unchanged.

US market only; negligible regional effect.

None

Counterpoint

Insider may be diversifying; could be unrelated to company outlook.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Biotech firm developing treatments for rare skin diseases.

  • Matsuda Masaru

    Company officer executing a pre‑arranged 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.